Why the study?
Is cilostazol an effective and safe substitute for aspirin in Chinese patients with aspirin intolerance requiring DAPT after coronary DES implantation?
Is cilostazol an effective and safe substitute for aspirin in Chinese patients with aspirin intolerance requiring DAPT after coronary DES implantation?
Cilostazol may serve as a viable alternative to aspirin for dual antiplatelet therapy in patients with aspirin intolerance following DES implantation.
Answers are grounded in this paper and cite their sources.
May support cilostazol substitution in aspirin-intolerant patients post-DES; hypothesis-generating, leaves open need for RCTs.
In the current study, cilostazol is a good substitute for aspirin in patients who have aspirin intolerance but need DAPT after coronary DES implantation in China. However, large-scale randomized controlled trials were still required to further confirm its efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: